Evaluating Z-FA-FMK, a host cathepsin L protease inhibitor, as a potent and broad-spectrum antiviral therapy against SARS-CoV-2 and related coronaviruses
Ju Hwan Jeong(Korea Research Institute of Bioscience and Biotechnology), Min‐Suk Song(Chungbuk National University), Seong Cheol Min(Chungbuk National University), Yun Hee Baek(Chungbuk National University), Young Ki Choi(Sungkyunkwan University), Santosh Chokkakula(Chungbuk National University), Beom Kyu Kim(Chungbuk National University), Sol Oh(Chungbuk National University), Jihyun Park(Chungbuk National University), Joo-Yeon Lee(International Vaccine Institute), Jang‐Hoon Choi(Korea National Institute of Health), Sang‐Mu Shim(Korea National Institute of Health), Eung‐Gook Kim(Chungbuk National University)
Cited by 7
Related Papers
Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19
|Scientific Reports|2020|99
Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice
|Antiviral Research|2022|82
Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy
|Microorganisms|2023|77
SARS-CoV-2 drug resistance and therapeutic approaches
|Heliyon|2025|44
Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain
|Experimental & Molecular Medicine|2016|28